Citigroup maintains Buy rating, raises Ionis Pharmaceuticals PT to $84 from $69.

Citigroup maintains Buy rating, raises Ionis Pharmaceuticals PT to $84 from $69.

Citigroup analyst David Lebowitz has maintained a "Buy" rating on Ionis Pharmaceuticals (IONS, Financial) while raising the price target from $69.00 to $84.00, marking a significant increase of 22.03%. This adjustment reflects a positive outlook for the biotechnology company. The rating remains unchanged from the prior "Buy" status, according to the latest data dated September 2, 2025 [1].

Ionis Pharmaceuticals is a leading developer of antisense technology, focusing on discovering and developing novel drugs for a variety of diseases, including cardiovascular, metabolic, neurological, and rare diseases. The company has a robust pipeline of drugs, with notable achievements such as the launch of Spinraza in 2016 for spinal muscular atrophy and ALS drug Qalsody in 2023 [2].

Analysts have shown a positive consensus towards Ionis Pharmaceuticals. Based on the one-year price targets offered by 24 analysts, the average target price for Ionis Pharmaceuticals Inc (IONS, Financial) is $60.09, with a high estimate of $83.00 and a low estimate of $40.00. The average target implies an upside of 6.70% from the current price of $56.32 [3].

The company's financial health is bolstered by a $2.3 billion cash reserve, which provides a buffer against regulatory risks. Additionally, Ionis Pharmaceuticals' strategic partnerships, such as the one with AstraZeneca for the polyneuropathy drug Wainua, further enhance its market position [2].

Ionis Pharmaceuticals stands at the precipice of a transformative year in 2025, driven by the clinical and commercial success of Olezarsen (Tryngolza) and a pipeline of high-conviction catalysts. Olezarsen has demonstrated significant reductions in triglycerides and acute pancreatitis events in pivotal Phase 3 trials, positioning it as a first-in-class therapy with blockbuster potential [2].

In conclusion, Citigroup's latest rating and price target adjustment for Ionis Pharmaceuticals reflect a positive outlook on the company's future prospects. The combination of a strong pipeline, strategic partnerships, and robust financial health positions Ionis Pharmaceuticals as a promising investment opportunity.

References:
[1] https://www.gurufocus.com/news/3090889/needham-analyst-joseph-stringer-raises-ionis-pharmaceuticals-ions-price-target-ions-stock-news
[2] https://www.ainvest.com/news/ionis-pharmaceuticals-high-conviction-buy-pivotal-data-launch-timeline-2025-2509/
[3] https://www.marketbeat.com/stocks/NASDAQ/IONS/forecast/